On January 7th, 2020, NMPA published a new guideline on “Real-World Evidence that defines Real-World Data (RWD) and Real-World Evidence (RWE) terms and clarifies their use during drugs’ research and development and registration in China.
Download our Whitepaper for a summary of the important implications introduced by this new guideline. 
Scroll to Top